Premium
Newborn screening strategy for cystic fibrosis: a field study in an area with high allelic heterogeneity
Author(s) -
Castellani C,
Bonizzato A,
Cabrini G,
Mastella G
Publication year - 1997
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1997.tb08920.x
Subject(s) - cystic fibrosis , lactase , medicine , trypsin , meconium ileus , incidence (geometry) , mutation , allele , gastroenterology , meconium , newborn screening , pediatrics , pregnancy , genetics , enzyme , biology , fetus , biochemistry , gene , physics , optics
To verify to what extent mutation analysis on blood spot could improve cystic fibrosis neonatal screening in an area with high allelic heterogeneity, we designed a special protocol. Spot trypsin estimation at birth, trypsin re‐testing after 1 month, meconium lactase testing and mutation analysis of ΔF508, R1162X and N1303K, were retrospectively clustered according to different patterns (trypsin/lactase/mutation; trypsin/ lactase/re‐testing; trypsin/mutation) and compared. The programme, which lasted 2 years (1993‐94) and covered most of North‐eastern Italy, included 95 553 screened newborns. Thirty‐four affected babies were detected by screening and one by meconium ileus (incidence 1/2730). The combined use of trypsin, lactase and mutation analysis in cystic fibrosis neonatal screening permits a better sensitivity compared to the two other combinations (34 diagnoses vs 32 in both cases). Moreover, the higher specificity of the former method (false positives 42 vs 148) allows a reduction of recalls, which cause considerable anxiety. We confirm in trypsin‐positive newborns an increased frequency of cystic fibrosis heterozygotes (1/17).